Market Intelligence, Clinical Progress, and High-Purity Reagents for Thrombocytopenia & Myeloproliferative Neoplasm Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for TPOR/MPL/CD110 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (WT) | TPOR/MPL/CD110 ECD-Fc Fusion Protein (Gln26-Trp491, Human IgG1 Fc). High purity (>95%), Endotoxin <1EU/ug. HEK293 expressed, native glycosylation. Sequence verified. | View TPOR Products |
| Antigen (Mutant) | TPOR/MPL/CD110 W515L/K Mutant ECD-Fc Proteins. Oncogenic mutants for MPN antagonist screening. High purity (>95%), Sequence verified. | View TPOR Products |
| Gene Delivery | TPOR/MPL/CD110 Promise-ORF / Lentivirus Premade Particles. Full-length ORF (WT or W515L) for stable Ba/F3 or HEK293 cell lines. High titer (>10^8 TU/mL). | View TPOR Products |
| Benchmark Ab | Clinical Benchmark Antibodies (Romiplostim Biosimilar format). Recombinant positive controls for competitive binding and proliferation assays. | View TPOR Products |
| Validator | TPOR/MPL/CD110 siRNA Set (3 unique sequences). For knockdown verification and specificity controls. | View TPOR Products |
| Related Target: TPO (THPO) | Thrombopoietin. Natural ligand; essential for agonist competition and displacement assays. High purity (>95%). | View TPO Products |
| Related Target: CALR | Calreticulin (WT and Mutant). Mutant CALR binds TPOR to drive MPN pathogenesis; key for ET/PMF models. | View CALR Products |
| Related Target: JAK2 | JAK2 (WT and V617F Mutant) Recombinant Protein. Downstream signaling node; critical for MPN resistance and combination profiling. | View JAK2 Products |
Critical Assay Challenges & Technical Specifications
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species evaluation (Human, Mouse, Cynomolgus ortholog screening for PK/PD) | Human/Mouse/Cynomolgus ortholog ECD-Fc proteins available with >95% purity, Sequence Verified by mass spec. |
| Oncogenic Mutant Selectivity (W515L/K vs WT) | Matched WT and W515L/K mutant proteins produced in parallel HEK293 lots for differential screening. |
| TPO Competitive Binding (Agonist Mechanism) | High-affinity ECD-Fc with native glycosylation for SPR/BLI-based displacement assays. |
| Constitutive Activity Screening (MPN) | Lentivirus for stable Ba/F3-TPOR cell line generation (preserves signaling conformation). |
| False Positive Elimination | Validated siRNA set for target-specificity confirmation in cell-based dimerization assays. |
| Cytokine receptor counter-screening | EPOR, G-CSFR homolog panel proteins strictly verified by mass spec to ensure selectivity. |
Live TPOR/MPL/CD110 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic landscape surrounding the Thrombopoietin Receptor (TPOR/MPL/CD110) has matured significantly over the past two decades, yet remains a hotbed for second-generation innovation. While first-generation TPO receptor agonists (TPO-RAs) such as Romiplostim, Eltrombopag, Avatrombopag, and Lusutrombopag have revolutionized the management of immune thrombocytopenia (ITP), chronic liver disease (CLD) associated thrombocytopenia, and severe aplastic anemia (SAA), the clinical race is shifting toward two distinct new frontiers.
First, developers are designing next-generation oral small molecules and peptibodies with enhanced pharmacokinetic profiles, no dietary restrictions, and minimal risk of bone marrow reticulin deposition or hepatotoxicity. Second, there is an aggressive shift toward oncology and hematological malignancies: specifically targeting mutated MPL (W515L/K, S505N) and mutant Calreticulin (CALR)-driven myeloproliferative neoplasms (MPNs) like essential thrombocythemia (ET) and primary myelofibrosis (PMF). In this oncological setting, the goal pivots from agonism to selective antagonism—deploying monoclonal antibodies, bispecifics, and antibody-drug conjugates (ADCs) to selectively eliminate oncogenic megakaryocytic lineages without suppressing normal hematopoietic stem cells. As combination therapies with JAK2 inhibitors (e.g., Ruxolitinib) enter Phase II, assays must resolve dual-target pharmacodynamics.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Agonist | Novartis, Sobi/Alexion, Shionogi, Hengrui | ITP, CLD Thrombocytopenia, SAA | Allosteric / Transmembrane Binding Assays (Need stable cell lines via high-titer Lentivirus premade particles). |
| Peptibody / Peptide-Fc Fusion | Amgen (Romiplostim), Biothera, 三生制药 | Refractory ITP, CIT (Chemotherapy-Induced Thrombocytopenia) | ECD Dimerization & Binding Assays (Need sequence-verified, native glycosylated HEK293 ECD-Fc proteins). |
| Monoclonal Antagonists / ADCs | Various Preclinical & Biotech Innovators | Myeloproliferative Neoplasms (MPNs), ET | Mutant Selectivity Screening (Need high-purity W515L/W515K mutant proteins vs. Wild-Type counter-screens). |
| Bispecific Antibodies | Emerging Immuno-Oncology Pipelines | Megakaryoblastic Leukemia, Hematopoietic Stem Cell Expansion | Epitope Specificity & Cross-Reactivity Assays (Need strictly controlled ortholog panels and clinical benchmark Abs). |
| JAK2/MPL Combinations | Novartis, Incyte | Myelofibrosis | Phosphorylation Assays (pSTAT5, pJAK2) with dual-target pharmacodynamic readout. |
Molecular Differentiation & Assay Strategy
To develop best-in-class TPOR/MPL therapeutics, the following molecular differentiation dimensions must be addressed:
Affinity & Binding Mode:
- Agonists must mimic natural TPO to induce homodimerization and JAK2/STAT5 activation. Moderate affinity (Kd ~1-10 nM) is desirable to avoid overstimulation and receptor desensitization.
- Antagonists (MPN direction) require high affinity (Kd <100 pM) to fully block mutant receptor signaling, especially for W515L conformational changes.
Mutant Selectivity:
- W515L mutation induces a subtle change in the ECD orientation. Assays using FRET/TR-FRET with labeled WT and W515L ECD-Fc proteins can identify conformation-specific binders.
- TarMart provides matched WT and W515L/K proteins expressed in HEK293 for differential screening.
Cross-Species Reactivity:
- Human, Mouse, and Cynomolgus orthologs are available with >95% purity. Sequence verified by mass spec to ensure epitope conservation.
Assay System Recommendations:
- Ba/F3-TPOR stable cell line proliferation assay (gold standard for functional activity).
- SPR/BLI affinity measurement using HEK293-expressed ECD-Fc proteins.
- Mutant selectivity panel: W515L, W515K, S505N vs WT.
- Counter-screening against EPOR, G-CSFR family.
- siRNA knockdown specificity verification.
TarMart tools: ECD-Fc proteins (HEK293, >95% purity, <1 EU/ug), lentivirus particles for stable cell lines, clinical benchmark antibodies, and siRNA sets.